Objective: This project seeks to identify the top 30 drugs most commonly associated With gastrointestinal haemorrhage in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), as well as their respective reporting odds ratios (RORs). Methods: We extracted case identifiers, adverse events, and attributed medications for entries in the FAERS database from the first quarter of 2004 to the second quarter of 2024. Entries were split into datasets based on whether or they contained the word “gastrointestinal haemorrhage.” The medications most commonly associated with gastrointestinal haemorrhage were then identified.We employed signal detection methodologies to ascertain whether these drugs elicited significant signals, including reporting odds ratio(ROR),time-to-onset (TTO). Results: We extracted 53,769,390 entries, of which 307,607 contain the word “gastrointestinal haemorrhage.” The 30 most frequently appearing medications were then ranked by ROR values with associated 95% confidence intervals. The three medications with the greatest association with headaches were Rivaroxaban (ROR 29.33, 95% CI 28.98– 29.67), Dabigatran (ROR 22.12, 95% CI 21.74– 22.5), and Aspirin (ROR 20.99, 95% CI 20.64– 21.36). Anticoagulants and Antiplatelet, Antirheumatic and immunomodulatory were most commonly associated with gastrointestinal haemorrhage.A TTO analysis was conducted for the 30 drugs that generated risk signals, revealing that all drugs exhibited an early failure type. The median TTO for Ibuprofen was 11 days, the shortest of all the drugs, while the median TTO for Ambrisentan was 379 days, the longest of all the drugs. Conclusion: Our study offers a potential list of the medication classes commonly as-sociated with iatrogenic gastrointestinal haemorrhage